Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,335,206
  • Shares Outstanding, K 296,870
  • Annual Sales, $ 452,480 K
  • Annual Income, $ 154,230 K
  • 36-Month Beta 2.09
  • Price/Sales 14.00
  • Price/Cash Flow 39.01
  • Price/Book 9.46

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.37 +9.91%
on 06/25/18
22.21 -4.14%
on 07/13/18
+0.66 (+3.20%)
since 06/20/18
3-Month
18.50 +15.08%
on 05/10/18
23.76 -10.40%
on 05/03/18
+0.42 (+2.01%)
since 04/20/18
52-Week
18.50 +15.08%
on 05/10/18
32.50 -34.49%
on 10/16/17
-5.70 (-21.12%)
since 07/20/17

Most Recent Stories

More News
Roche's Tecentriq Gets Breakthrough Therapy Status for HCC

The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.

ILMN : 311.15 (+0.66%)
EXEL : 21.29 (-0.23%)
RHHBY : 29.4700 (+1.94%)
VNDA : 20.80 (-0.72%)
Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2018 financial results will be released on Wednesday, August 1, 2018 after the markets close. At 5:00 p.m. EDT...

EXEL : 21.29 (-0.23%)
20.0% Return Seen to Date on SmarTrend Exelixis Inc Call (EXEL)

SmarTrend identified a Downtrend for Exelixis Inc (NASDAQ:EXEL) on February 28th, 2018 at $26.69. In approximately 4 months, Exelixis Inc has returned 19.99% as of today's recent price of $21.35.

EXEL : 21.29 (-0.23%)
Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine

Exelixis, Inc. (Nasdaq: EXEL) today announced that The New England Journal of Medicine (NEJM) published results from the CELESTIAL phase 3 pivotal trial of cabozantinib in patients...

EXEL : 21.29 (-0.23%)
Exelixis (EXEL) Jumps: Stock Rises 8%

Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

GHDX : 57.34 (-1.66%)
EXEL : 21.29 (-0.23%)
Exelixis to Be Added to the S&P MidCap 400 Index

Exelixis, Inc. (Nasdaq: EXEL) today announced that it will be added to Standard & Poor's (S&P) MidCap 400 index, effective prior to the open of trading on Monday, July 2. The company will...

SPGI : 212.33 (+0.50%)
EXEL : 21.29 (-0.23%)
GE, Lam Research and Lennar climb while Akamai stumbles

NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:

LEN : 54.68 (-0.83%)
XOM : 81.40 (-0.74%)
AKAM : 78.91 (+0.86%)
LRCX : 177.81 (-0.24%)
EXEL : 21.29 (-0.23%)
Exelixis Inc Down 21.0% Since SmarTrend Downtrend Call (EXEL)

SmarTrend identified a Downtrend for Exelixis Inc (NASDAQ:EXEL) on February 28th, 2018 at $26.69. In approximately 4 months, Exelixis Inc has returned 21.04% as of today's recent price of $21.07.

EXEL : 21.29 (-0.23%)
Watch for Exelixis Inc to Potentially Pullback After Gaining 8.24% Yesterday

Exelixis Inc (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $20.72 to a high of $21.82. Yesterday, the shares gained 8.2%, which took the trading range above the 3-day high of $21.00...

EXEL : 21.29 (-0.23%)
Today's Research Reports on Trending Tickers: Exelixis and Zafgen

NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of...

EXEL : 21.29 (-0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade EXEL with:

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 21.63
1st Resistance Point 21.46
Last Price 21.29
1st Support Level 21.12
2nd Support Level 20.95

See More

52-Week High 32.50
Fibonacci 61.8% 27.15
Fibonacci 50% 25.50
Fibonacci 38.2% 23.85
Last Price 21.29
52-Week Low 18.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar